중등도에서 중증 활동성 크론병 환자를 대상으로 구셀쿠맙 대 리산키주맙 비교 연구 (CHARGE)
중등도에서 중증의 활동성 크론병 환자에서 구셀쿠맙 대 리산키주맙의 효능과 안전성을 비교하는 3b상, 다기관, 무작위 배정, 공개 라벨, 능동 대조 임상 연구
The purpose of this study is to assess how well guselkumab works when compared to risankizumab in participants with moderately to severely active Crohn's Disease (CD; a long-term condition causing severe inflammation of the intestinal tract).
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 3단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Maastricht, 네덜란드, 6229 HX
- 모병
- Maastricht UMC
-
Nijmegen, 네덜란드, 6525 GA
- 모병
- Radboud Umcn
-
Tilburg, 네덜란드, 5022 GC
- 모병
- St. Elisabeth Ziekenhuis
-
-
-
-
-
Aarhus C, 덴마크, 8200
- 모병
- Aarhus University Hospital
-
Esbjerg, 덴마크, 6700
- 모병
- Sydvestjysk Sygehus
-
Gistrup, 덴마크, 9260
- 모병
- NAU New Aalborg University Hospital
-
Herlev, 덴마크, 2730
- 모병
- Herlev Hospital
-
Hilleroed, 덴마크, 3400
- 모병
- Nordsjaellands Hospital, Hillerod
-
Hvidovre, 덴마크, 2650
- 모병
- Hvidovre Hospital
-
København NV, 덴마크, 2400
- 모병
- Bispebjerg Hospital
-
Odense C, 덴마크, 5000
- 모병
- Odense UH og Svendberg sygehus
-
-
-
-
-
Berlin, 독일, 10825
- 모병
- GASTRO-Studien
-
Berlin, 독일, 12203
- 모병
- Charite Universitaetsmedizin Berlin - Campus Benjamin Franklin (CBF)
-
Erlangen, 독일, 91054
- 모병
- Universitatsklinikum Erlangen
-
Grevenbroich, 독일, 41515
- 모병
- Praxiszentrum Fur Gastroenterologie und Endoskopie Grevenbroich
-
Jena, 독일, 07747
- 모병
- Universitatsklinikum Jena
-
Kiel, 독일, 24105
- 모병
- Universitatsklinikum Schleswig Holstein Kiel
-
Ludwigshafen am Rhein, 독일, 67067
- 모병
- St. Marien und St. Annastiftskrankenhaus
-
Mannheim, 독일, 68167
- 모병
- Universitaetsklinikum Mannheim
-
München, 독일, 81675
- 모병
- Klinikum rechts der Isar der TU Munchen
-
-
-
-
Alabama
-
Dothan, Alabama, 미국, 36305
- 모병
- Digestive Health Specialists of the Southeast
-
Mobile, Alabama, 미국, 36608
- 모병
- East View Medical Research
-
-
California
-
Anaheim, California, 미국, 92805
- 모병
- Clinnova Research
-
Lancaster, California, 미국, 93534
- 모병
- Gastro Care Institute
-
Los Alamitos, California, 미국, 90720
- 모병
- United Gastroenterologists
-
Los Angeles, California, 미국, 90048
- 모병
- TLC Clinical Research Inc
-
Los Angeles, California, 미국, 90067
- 모병
- GastroIntestinal Bioscience
-
San Diego, California, 미국, 92123
- 모병
- Medical Associates Research Group, Inc.
-
-
Colorado
-
Colorado Springs, Colorado, 미국, 80907
- 모병
- Peak Gastroenterology Associates
-
-
Connecticut
-
Hamden, Connecticut, 미국, 06518
- 모병
- Medical Research Center of Connecticut
-
-
Florida
-
Jacksonville, Florida, 미국, 32258
- 모병
- Green Leaf Clinical Trials
-
Miami, Florida, 미국, 33157-6575
- 모병
- Sanchez Clinical Research, Inc
-
Miami, Florida, 미국, 33186
- 모병
- Biodax Medical Research Trials
-
Naples, Florida, 미국, 34102
- 모병
- GI Pros Research
-
Orlando, Florida, 미국, 32806
- 모병
- Orlando Health Digestive Health Institute
-
Tampa, Florida, 미국, 33609
- 모병
- GCP Clinical Research
-
-
Georgia
-
Atlanta, Georgia, 미국, 30310
- 모병
- Morehouse School of Medicine
-
Atlanta, Georgia, 미국, 30342
- 정지된
- Atlanta Gastroenterology Associates
-
Macon, Georgia, 미국, 31201
- 모병
- Gastroenterology Associates of Central GA
-
-
Illinois
-
Northbrook, Illinois, 미국, 60062
- 모병
- Comprehensive Gastrointestinal Health Libertyville
-
-
Iowa
-
Clive, Iowa, 미국, 50325
- 모병
- Heartland Medical Research Inc
-
-
Kansas
-
Topeka, Kansas, 미국, 66606
- 모병
- Cotton-O'Neil Clinical Research Center
-
-
Louisiana
-
Lafayette, Louisiana, 미국, 70503
- 모병
- Gastroenterology Clinic of Acadiana
-
Shreveport, Louisiana, 미국, 71103
- 모병
- Louisiana State University Health Sciences Center Shreveport
-
-
Maryland
-
Glen Burnie, Maryland, 미국, 21061
- 모병
- Woodholme Gastroenterology Associates
-
-
Massachusetts
-
New Bedford, Massachusetts, 미국, 02740
- 모병
- Lucida Clinical Trials
-
-
Michigan
-
Farmington Hills, Michigan, 미국, 48334
- 모병
- Michigan Center of Medical Research
-
-
New York
-
Carmel, New York, 미국, 10512
- 모병
- Westchester Putnam Gastroenterology
-
New York, New York, 미국, 10028
- 모병
- New York Gastroenterology Associates
-
New York, New York, 미국, 10075
- 정지된
- Lenox Hill Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, 미국, 27599 7080
- 모병
- University of North Carolina at Chapel Hill
-
Charlotte, North Carolina, 미국, 28207
- 모병
- Charlotte Gastroenterology and Hepatology, PLLC
-
-
Ohio
-
Mentor, Ohio, 미국, 44060
- 모병
- Great Lakes Gastroenterology Research, LLC
-
-
Oklahoma
-
Oklahoma City, Oklahoma, 미국, 73114
- 모병
- Digestive Disease Specialists Inc
-
-
Pennsylvania
-
Uniontown, Pennsylvania, 미국, 15401
- 모병
- Frontier Clinical Research
-
-
South Carolina
-
Summerville, South Carolina, 미국, 29486
- 모병
- Palmetto Primary and Specialty Care Physicians, Charleston
-
-
Texas
-
Carrollton, Texas, 미국, 75010
- 모병
- DFW Clinical Trials
-
Lubbock, Texas, 미국, 79424
- 모병
- Lubbock Gastroenterology
-
San Antonio, Texas, 미국, 78229
- 모병
- Gastroenterology Research of America, LLC
-
San Antonio, Texas, 미국, 78229
- 모병
- Southern Star Research Institute, LLC
-
Tyler, Texas, 미국, 75708
- 모병
- The University of Texas Health Science Center at Tyler
-
-
-
-
-
Brussels, 벨기에, 1200
- 모병
- Cliniques Universitaires Saint Luc
-
Brussels, 벨기에, 1070
- 모병
- ULB Erasme Ziekenhuis
-
Genk, 벨기에, 3600
- 모병
- Ziekenhuis Oost-Limburg
-
Ghent, 벨기에, 9000
- 모병
- Ghent University Hospital
-
Leuven, 벨기에, 3000
- 모병
- Universitair Ziekenhuis Leuven
-
Liège, 벨기에, 4000
- 모병
- CHU de Liege
-
Roeselare, 벨기에, 8800
- 모병
- Algemeen Ziekenhuis Delta
-
-
-
-
-
Linköping, 스웨덴, 58185
- 모병
- Linkoping University Hospital
-
Mölndal, 스웨덴, 431 30
- 모병
- Sahlgrenska Universitetssjukhuset, Mölndal Sjukhus
-
Stockholm, 스웨덴, 171 76
- 모병
- Karolinska Universitetssjukhuset
-
Stockholm, 스웨덴, 116 30
- 모병
- Ersta sjukhus
-
Stockholm, 스웨덴, 118 83
- 모병
- Sodersjukhuset
-
Uppsala, 스웨덴, 751 85
- 모병
- Akademiska Sjukhuset
-
-
-
-
-
Alicante, 스페인, 03010
- 모병
- Hosp. Gral. Univ. Dr. Balmis
-
Barcelona, 스페인, 08036
- 모병
- Hosp. Clinic de Barcelona
-
Ferrol, 스페인, 15405
- 모병
- Hosp. Arquitecto Marcide
-
Gijón, 스페인, 33394
- 모병
- Hosp. de Cabuenes
-
Girona, 스페인, 17007
- 모병
- Hosp. Univ. Dr. Josep Trueta
-
Madrid, 스페인, 28850
- 모병
- Hosp. Univ. de Torrejon
-
Navarra, 스페인, 31008
- 모병
- Hosp. de Navarra
-
Santiago de Compostela, 스페인, 15706
- 모병
- Hosp. Clinico Univ. de Santiago
-
Seville, 스페인, 41009
- 모병
- Hosp. Virgen Macarena
-
-
-
-
-
Banská Bystrica, 슬로바키아, 975 17
- 모병
- FNsP F. D. Roosevelta Banska Bystrica
-
Bratislava, 슬로바키아, 811 09
- 모병
- Cliniq s.r.o.
-
Košice, 슬로바키아, 040 13
- 모병
- ENDOMED s.r.o
-
Nové Zámky, 슬로바키아, 940 34
- 모병
- Fakultna nemocnica s poliklinikou Nove Zamky
-
Prešov, 슬로바키아, 080 01
- 모병
- GASTRO I. s.r.o.
-
Prešov, 슬로바키아, 080 01
- 모병
- Gastro LM s.r.o.
-
Rimavská Sobota, 슬로바키아, 979 12
- 모병
- Vseobecna nemocnica Rimavska Sobota
-
-
-
-
-
Greater London, 영국, E1 2AJ
- 모병
- Barts Health NHS Trust
-
Greater London, 영국, NW10 7NS
- 모병
- London North West University Healthcare NHS Trust
-
Iselworth, 영국, TW7 6AF
- 모병
- West Middlesex University Hospital
-
London, 영국, NW3 2QG
- 모병
- Royal Free Hospital
-
London, 영국, W120HS
- 모병
- Imperial College London
-
London, 영국, NW1 2PG
- 모병
- University College London Hospitals Nhs Foundation Trust
-
London, 영국, SW10 9NH
- 모병
- Chelsea And Westminster Hospital
-
Norwich, 영국, NR4 7UQ
- 모병
- Norfolk and Norwich University Hospital
-
Wolverhampton, 영국, WV10 0QP
- 모병
- New Cross Hospital
-
-
-
-
-
Graz, 오스트리아, 8036
- 모병
- LKH-Univ. Klinikum Graz
-
Innsbruck, 오스트리아, 6020
- 모병
- Medizinische Universitatsklinik Innsbruck
-
Linz, 오스트리아, 4021
- 모병
- Kepler Universitatsklinikum GmbH
-
Salzburg, 오스트리아, 5020
- 모병
- LKH - Universitätsklinikum der PMU Salzburg
-
Vienna, 오스트리아, 1090
- 모병
- Medical University Vienna
-
Vienna, 오스트리아, 1020
- 모병
- Krankenhaus der Barmherzigen Brüder
-
Wels, 오스트리아, 4600
- 모병
- Klinikum Wels Grieskirchen
-
Wiener Neustadt, 오스트리아, 2700
- 모병
- Universitatsklinikum Wiener Neustadt
-
-
-
-
-
Bologna, 이탈리아, 40138
- 모병
- A O U Sant Orsola Malpighi
-
Bolzano, 이탈리아, 39100
- 모병
- Azienda Sanitaria dell'Alto Adige - Ospedale di Bolzano
-
Genova, 이탈리아, 16132
- 모병
- Azienda Ospedaliero Universitaria San Martino
-
Milan, 이탈리아, 20132
- 모병
- IRCCS Ospedale San Raffaele
-
Roma, 이탈리아, 00168
- 모병
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, 이탈리아, 20089
- 모병
- Istituto Clinico Humanitas
-
Torino, 이탈리아, 10128
- 모병
- Ospedale Mauriziano Torino
-
-
-
-
-
Changzhou, 중국, 213018
- 모병
- Changzhou No 2 Peoples Hospital
-
Chongqing, 중국, 400014
- 모병
- Chongqing General Hospital
-
Fuzhou, 중국, 350005
- 모병
- The First Affiliated Hospital of Fujian Medical University
-
Guangzhou, 중국, 510655
- 모병
- The Sixth Affiliated Hospital Sun Yat sen University
-
Guangzhou, 중국, 510261
- 모병
- The Second Affiliated Hospital of Guangzhou Medical University
-
Nanjing, 중국, 210009
- 모병
- Zhongda Hospital Southeast University
-
Wuhan, 중국, 430060
- 모병
- Renmin Hospital of Wuhan University
-
-
-
-
-
Brno, 체코, 62500
- 모병
- Fakultni nemocnice Brno
-
Brno, 체코, 636 00
- 모병
- Vojenska nemocnice Brno
-
Hradec Kralova, 체코, 500 02
- 모병
- Gastroenterologie, s.r.o., Hradec Kralove
-
Hradec Králové, 체코, 500 12
- 모병
- Hepato-gastroenterologie HK, s.r.o.
-
Ostrava-Poruba, 체코, 708 00
- 모병
- Fakultni Nemocnice Ostrava
-
Prague, 체코, 100 00
- 모병
- Fakultni nemocnice Kralovske Vinohrady
-
Prague, 체코, 14000
- 모병
- Fakultni Thomayerova nemocnice
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T5R 1W2
- 모병
- Gastroenterology and Internal Medicine Research Institute (GIRI)
-
-
British Columbia
-
Vancouver, British Columbia, 캐나다, V6Z 2K5
- 모병
- GIRI Gastrointestinal Research Institute
-
-
Ontario
-
Hamilton, Ontario, 캐나다, L8N1Y2
- 모병
- Charlton Digestive Disease Centre
-
London, Ontario, 캐나다, N6K 1M6
- 모병
- London Digestive Disease Institute
-
Oshawa, Ontario, 캐나다, L1J 0C7
- 모병
- Taunton Surgical Centre
-
Toronto, Ontario, 캐나다, M6A 3B4
- 모병
- Toronto Immune and Digestive Health Institute Inc
-
-
Quebec
-
Montreal, Quebec, 캐나다, H3H1E3
- 모병
- Clinique IMD
-
Montreal, Quebec, 캐나다, H2X 0C1
- 모병
- Centre Hospitalier de l'Universite de Montreal
-
-
-
-
-
Bydgoszcz, 폴란드, 85 229
- 모병
- Centrum Medyczne Medis ManerMed Sp Z O O
-
Krakow, 폴란드, 30363
- 모병
- Centrum Medyczne Plejady
-
Krakow, 폴란드, 31-513
- 모병
- Centrum Medyczne Promed
-
Rzeszów, 폴란드, 35-326
- 모병
- Centrum Medyczne 'Medyk' Sp. z o.o. K.
-
Szczecin, 폴란드, 71-434
- 모병
- Twoja Przychodnia - Szczecinskie Centrum Medyczne
-
Torun, 폴란드, 87 100
- 모병
- GASTROMED Kopon Zmudzinski i wspolnicy SP j Specjalistyczne Centrum Gastrologii i Endoskopii
-
Warsaw, 폴란드, 02-781
- 모병
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, 폴란드, 04 501
- 모병
- Medical Network Sp z o o
-
-
-
-
-
Amiens, 프랑스, 80000
- 모병
- CHU Amiens Picardie
-
Clermont-Ferrand, 프랑스, 63000
- 모병
- Clermont Ferrand University Hospital
-
Marseille, 프랑스, 13015
- 모병
- Aphm - Hopital Nord
-
Nantes, 프랑스, 44000
- 모병
- CHU Nantes - Hotel Dieu
-
Neuilly-sur-Seine, 프랑스, 92200
- 모병
- Clinique Ambroise Pare
-
Nîmes, 프랑스, 30900
- 모병
- CHU Nimes
-
Paris, 프랑스, 75018
- 모병
- APHP - Hopital Bichat - Claude Bernard
-
Paris, 프랑스, 75012
- 모병
- Aphp Hopital Saint Antoine
-
Pierre-Bénite, 프랑스, 69495
- 모병
- Hospices Civils de Lyon CHU Lyon Sud
-
Reims, 프랑스, 51100
- 모병
- CHU de Reims
-
Vandœuvre-lès-Nancy, 프랑스, 54511
- 모병
- Centre Hospitalier Universitaire de Nancy - Hôpital Central
-
Échirolles, 프랑스, 38130
- 모병
- Institut Prive MICI Clinique des Cedres
-
-
-
-
-
Budapest, 헝가리, 1088
- 모병
- Semmelweis Egyetem
-
Budapest, 헝가리, 1036
- 모병
- Obudai Egeszsegugyi Centrum Kft
-
Budapest, 헝가리, H-1136
- 모병
- Pannónia Magánorvosi Centrum Kft
-
Budapest, 헝가리, 1082
- 모병
- Semmelweis Egyetem 1
-
Budapest, 헝가리, 1083
- 모병
- Semmelweis Egyetem 2
-
Budapest, 헝가리, 1139
- 모병
- Endomedix
-
Gyöngyös, 헝가리, 3200
- 모병
- Clinexpert Gyongyos Kft
-
Szeged, 헝가리, 6725
- 모병
- Szegedi Tudomanyegyetem
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion criteria:
-
Has CD or fistulizing Crohn's Disease (CD) of at least 12 weeks' duration, with colitis, ileitis, or ileocolitis, confirmed at some time in the past by radiography, histology, and/or endoscopy
-
Have moderately to severely active CD, defined as baseline Crohn's Disease Activity Index (CDAI) score greater than or equal to (>=) 220 but less than or equal to (<=) 450
-
Baseline endoscopic evidence of active ileal and/or colonic CD as assessed by central endoscopy reading at the screening endoscopy defined as a screening Simple Endoscopic Score for Crohn's Disease (SES CD) >= 4 (for participants with isolated ileal disease) or >= 6 (for participants with colonic or ileocolonic disease), based on the presence of ulceration in any 1 of the 5 ileocolonic segments, resulting in the following specified ulceration component scores:
- a minimum score of 1 for the component of "size of ulcers" AND
- a minimum score of 1 for the component of "ulcerated surface"
-
In the opinion of the investigator, participant's disease is appropriate to treat with the maintenance dosing regimens utilized in the study
-
Adhere to the requirements for concomitant medications for the treatment of CD as mentioned in the protocol
Exclusion criteria
- Has complications of CD such as symptomatic strictures or stenoses, short gut syndrome, active draining stoma or significant fistulizing disease or any other manifestation anticipated to require surgery within the next year, could preclude the use of the CDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with guselkumab or risankizumab
- Currently has or is suspected to have an abscess
- Has an active fistula during screening or at Week 0 with an anticipated need for surgery
- Has had any kind of bowel resection within 24 weeks, or any other intra-abdominal or other major surgery within 12 weeks, before first dose of study intervention
- Currently has a malignancy or has a history of malignancy within 5 years before screening
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Guselkumab
Participants will receive guselkumab induction dose subcutaneously (SC) at Weeks 0, 4, and 8 followed by guselkumab maintenance dose SC once every 4 weeks (q4w) from Week 12 through Week 52. |
Guselkumab will be administered.
다른 이름들:
|
|
실험적: Risankizumab
Participants will receive risankizumab induction dose intravenously (IV) at Weeks 0, 4, and 8 followed by risankizumab maintenance dose SC once every 8 weeks (q8w) from Week 12 through Week 52. |
Risankizumab will be administered. |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Participants with Deep Remission at Week 52
기간: At Week 52
|
Deep remission is a composite endpoint defined as achieving both clinical remission and endoscopic remission at the participant level. Clinical remission is defined as Crohn's Disease Activity Index (CDAI) score less than (<) 150-point. CDAI will be assessed by collecting information on 8 different CD-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. In general, CDAI score ranges from 0 to approximately 600. Higher score indicates higher disease activity. Endoscopic remission is defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) less than or equal to (<=) 4 with at least a 2-point reduction from baseline and no sub score greater than (>) 1 in any individual component and score can range from 0 to 56. Higher scores indicating severe disease. |
At Week 52
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Composite Endpoint of Number of Participants with Clinical Remission and Endoscopic Response at Week 52
기간: At Week 52
|
Clinical remission is defined as CDAI score < 150-point. CDAI will be assessed by collecting information on 8 different CD-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. In general, CDAI score ranges from 0 to approximately 600. Higher score indicates higher disease activity. Endoscopic response is defined as >50 percent (%) improvement from baseline in the SES CD or SES-CD score <= 2 or a decrease of at least 2 points in participants with a baseline score of 4 and isolated ileal disease. This is a composite endpoint defined to measure achievement of both clinical remission and endoscopic response. |
At Week 52
|
|
Number of Participants with Endoscopic Remission at Week 52
기간: At Week 52
|
Endoscopic remission is defined as SES-CD <= 4 with at least a 2-point reduction from baseline and no sub score > 1 in any individual component and score can range from 0 to 56. Higher scores indicating severe disease. |
At Week 52
|
|
Number of Participants with Clinical Remission at Week 52
기간: At Week 52
|
Clinical remission is defined as CDAI score < 150-point. CDAI will be assessed by collecting information on 8 different CD-related variables: extra-intestinal manifestations, abdominal mass, weight, hematocrit, total number of liquid stools, abdominal pain/cramping, use of antidiarrheal drug(s), and/or opiates, and general well-being. In general, CDAI score ranges from 0 to approximately 600. Higher score indicates higher disease activity. |
At Week 52
|
|
Number of Participants with Steroid-Free Clinical Remission at Week 52
기간: At Week 52
|
Steroid-free clinical remission is defined as clinical remission at Week 52 and not receiving corticosteroids for at least 90 days prior to Week 52. Clinical remission is defined as CDAI score < 150-point. |
At Week 52
|
|
Number of Participants with Abnormalities in Laboratory Parameters
기간: Up to Week 148
|
Number of participants with abnormalities in laboratory parameters (hematology and chemistry) will be reported. |
Up to Week 148
|
|
Number of Participants With Change From Baseline in Laboratory Abnormalities
기간: Up to week 148
|
Number of participants with change from baseline in laboratory abnormalities (hematology and chemistry) will be reported. |
Up to week 148
|
|
Number of Participants with Adverse Events (AEs), Serious AEs and AEs Leading to Discontinuation of Study Intervention
기간: Up to Week 165
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 165
|
공동 작업자 및 조사자
수사관
수사관
- 연구 책임자: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- CNTO1959CRD3009
- CNTO1959CRD3009 (기타 식별자: Janssen Research & Development, LLC)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
미국에서 제조되어 미국에서 수출되는 제품
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .